Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.French protein pharmaceuticals developer Nautilus Biotech has reported making progress on next-generation interferon gamma, having developed a set of novel molecules engineered to create an enhanced IFN-gamma.
Subscribe to our email newsletter
If developed as a biopharmaceutical, this improved, highly stable version of IFN-gamma would allow less frequent injections of the drug.
The novel molecules, developed using Nautilus’ proprietary technology for protein improvement, are single mutants of IFN-gamma. They show significantly higher resistance to blood and intestinal proteases, while maintaining the native level of biological activity.
IFN-gamma is currently marketed for the treatment of chronic granulomatous disease and malignant osteopetrosis, and is in clinical trials for the treatment of idiopathic pulmonary fibrosis, certain forms of cancer and tuberculosis.
“Achieving higher stability is a key objective for the improvement of IFN-gamma, as it will increase the half-life of the molecule in the body and decrease the frequency of repeat treatments. This is one of the most important clinical criteria for any next generation IFN-gamma,” said Nautilus CEO, Manuel Vega.